Fiscal Year 2023 Fourth Quarter Highlights
Net sales of $91.1 million increased 4.7% compared to the prior-year quarter
Med Tech net sales of $26.5 million increased 17.2%
Med Device net sales of $64.6 million increased 0.3%
Gross margin of 50.9% declined 250 basis points year over year
GAAP loss per share of $0.54, inclusive of a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction announced on June 8, 2023
Adjusted earnings per share of $0.02
Cash and cash equivalents at May 31, 2023 were $44.6 million
On June 8, 2023, the Company completed the sale of its Dialysis and BioSentry Tract Sealant System Biopsy businesses to Merit Medical Systems, Inc. for $100 million in cash
Subsequent to quarter end, the Company completed enrollment in its PRESERVE study for the treatment of prostate cancer with NanoKnife
Full-Year 2023 Highlights
Net sales of $338.8 million increased 7.1% year over year
Gross margin declined
iData Research, a global consulting and market research firm, has just released exclusive research on the United States Gynecological Devices Market. The
Merit Medical Systems (NASDAQ:MMSI – Free Report) and Quipt Home Medical (NASDAQ:QIPT – Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation. Analyst Recommendations This is a breakdown of recent […]